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Abstract
 Several studies have shown support from the public toward theBackground.
use of medicinal marijuana. In this cross-sectional study, we assess the risk
perception to medicinal marijuana in a sample of medical students.
 To estimate risk perception, a visual scale that ranges from 0 cmMethods.
(without risk) to 10 cm (totally risky) was used. Risk perception was expressed
as the median of the cm marked over the scale. Differences among groups was
tested with the Mann-Whitney and Kruskal-Wallis tests, as appropriate.
 283 students participated in the study. Risk perception to medicinalResults.
marijuana was 4.22, paracetamol 1.56 and sedatives 5.0. A significant
difference in risk perception was observed in those that self-reported to smoke
and consume alcohol.
 Risk perception of medicinal marijuana is 4.22 in medicalConclusions.
students of northeast of Mexico. Students may underestimate its adverse
effects. More studies with respect to this are needed.
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Introduction
Several studies have showed the potential benefits of medicinal 
marijuana (MM) for the treatment of some illnesses, such as pain 
in cancer, multiple sclerosis, Alzheimer’s disease, post-traumatic 
stress disorder, epilepsy, Crohn’s disease, and glaucoma1,2. However, 
like other drugs, MM is not exempt from serious adverse effects, 
such as psychiatric disorders, euphoria, disorientation, confusion, 
somnolence, and fatigue; therefore, it should be used with extreme 
caution3. Legally, physicians cannot prescribe MM; however, in 
some countries, they can recommend its use when they consider it 
necessary. Some recommendations on how to prescribe marijuana 
for the care of patients have been published previously4.
On the other hand, risk perceptions towards medicinal drugs 
have been reported that influence in the prescribing behavior and 
the willingness of physicians to report adverse drug reactions. 
Knowing the risk perceived by medical students to drug prescrip-
tion is important, since it establishes the requirement of education 
regarding certain medicines, like MM. In this respect, there are no 
studies regarding the risk perception toward MM in the general 
population and among health professionals. The existing literature 
has focused mainly on attitudes and support toward its legaliza-
tion. Across countries, the factors associated with support for its 
legalization are political tolerance, ideology, and the views toward 
government5.
In Mexico, as in others countries, the use of MM was prohibited; 
however, in December 2016, the Senate approved the legaliza-
tion of MM and sent the bill to the Chamber of Representatives 
for ratification, which occurred on April 28, 2017. The next steps 
for its appropriate use include the publication of laws, regulations, 
and guidelines by the Health Ministry, medical schools, and medi-
cal associations. While this continues, it is important that health 
professionals be updated on this topic, so that they can ration-
ally recommend the use of MM. To achieve this, a first approach 
would be to know the attitudes and willingness to recommend the 
use of MM, and the risk perceived by physicians. In this study, we 
evaluate the risk perception of MM in medical students from 
northeast Mexico and determine associated factors.
Methods
Study design
A cross-sectional study that uses a visual scale to estimate risk 
perception of MM. The survey was applied during July and 
August 2017 in a public university from northeast of Mexico.
Participants
The inclusion criteria were as follow: Medical students of Universi-
dad Autónoma de Nuevo León, both genders, any semester of study, 
and ages older than 18 years. Participants with incomplete sur-
veys of second section were excluded. The medical students were 
contacted personally in the study areas and halls of the Faculty of 
Medicine. After obtaining verbal consent the survey was applied. 
This was self-administered with supervision. This study was per-
formed in accordance with the Declaration of Helsinki and was 
approved by the Ethics Committee of the Faculty of Medicine 
at Universidad Autónoma de Nuevo León (registration number 
PI17-00134). Only verbal consent was requested from participants 
because the study is of low risk. This type of consent was approved 
by the Ethics Committee.
Instrument
The survey used was composed of two sections, the first section, 
which was optional, collected demographic information, such as 
age, gender, semester of study, self-reported alcohol and smoking 
status (undefined level, only yes or no), and currently self- 
reported disease (unspecific, only yes or no). The second 
section evaluates the risk perception toward the use of MM. For 
this, a visual scale of 10 cm, from 0 cm (without risk) to 10 cm 
(completely risky), was used. Participants marked over the scale 
the risk that they perceived when MM is used. This section also 
contained two additional scales for paracetamol and sedatives, 
which act as relatively safe (negative control) and risky (positive 
control) drugs, respectively. The order of scales, including MM, 
was randomly allocated. The use of this visual 10-cm scales has 
been used previously in studies that assess the risk perception 
to other medicinal drugs6–8. The complete survey is available as 
Supplementary File 1.
Statistical analysis
Descriptive statistics is reported for demographic data. Risk 
perception was reported as the median of centimeters marked 
over the scale (from 0 to the mark). The results of risk perception 
were grouped by three age groups (18–20, 21–23 and >23 years), 
gender, semester of study (1–3, 4–7 and >7 semester), and self-
reported alcohol and smoking status. Differences among groups 
were evaluated with the Mann-Whitney and Kruskal-Wallis tests, 
as appropriate. The statistical package NCSS version 11 was used 
for all analysis. The level of significance was p < 0.05.
Results
Overall, the rate of response was 97%. In total 283 students were 
interviewed, of which 50.8% were men; 61% had an age range of 
21–23 years, and 62.8% were enrolled in semesters 8 or higher. 
In addition, 18.7% self-reported smoking, 48.1% consuming 
alcohol and 14.1% self-reported having a (unspecified) disease 
(Table 1).
Overall, the risk perception of MM was 4.22 cm, while for para-
cetamol and sedatives it was 1.56 and 5.00 cm, respectively 
(Figure 1). The observed differences among the three drugs 
were statistically significant (P < 0.05). This pattern was similar 
according to gender, age, semester of study, smoking and alcohol 
consumption and having some (unspecified) disease.
The analysis of individual drugs did not show a significant dif-
ference between gender, smoking and alcoholism status, having 
a disease, or among age groups and the semester of study in the 
risk perception of paracetamol and sedatives (Table 2). However, a 
significant difference was observed between self-reported smoking 
and alcohol consumption in the risk perception of MM. Those that 
self-reported smoking or alcoholism had a lower risk perception 
of MM.
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Table 1. Sociodemographic 
characteristics of participants.
Variable N %
Total 283 100
Gender 
Male 144 50.8
Female 139 49.1
Age* 
18–20 71 25.6
21–23 169 61.0
>24 37 13.4
Semester of study* 
1–3 49 17.4
4–7 56 19.9
>8 177 62.8
Smoking 
Yes 53 18.7
No 230 81.3
Alcohol 
Yes 136 48.1
No 147 51.9
Have a disease 
Yes 40 14.1
No 243 85.9
* Some data are missing due to 
participants that did not respond to the 
questions.
Table 2. Risk perception of medicinal marijuana (MM) by 
sociodemographic characteristics in medical students, using 
a visual scale with the median of cm.
Variable MM Paracetamol Sedatives P value
Total 4.22 1.56 5.00 <0.01
Gender 
Male 3.95 1.22 4.89 <0.01 
Female 4.44 1.44 5.00 <0.01 
P value 0.17 0.83 0.66
Age 
18–20 4.22 1.33 5.22 <0.01 
21–23 4.22 1.39 4.89 <0.01 
>24 4.00 1.56 4.89 <0.01 
P value 0.64 0.89 0.28
Semester of study 
1–3 3.00 1.22 4.84 <0.01 
4–7 4.67 1.22 4.78 <0.01 
>8 4.22 1.56 5.00 <0.01 
P value 0.19 0.36 0.69
Smoking 
Yes 2.78 1.22 4.89 <0.01 
No 4.39 1.44 5.00 <0.01 
P value 0.02 0.28 0.91
Alcohol 
Yes 3.67 1.22 5.00 <0.01 
No 4.56 1.56 4.89 <0.01 
P value 0.03 0.16 0.66
Have a disease 
Yes 4.11 2.56 4.78 <0.01 
No 4.22 1.33 5.00 <0.01 
P value 0.71 0.15 0.71
Figure 1. Risk perception of medicinal marijuana among medical students in northeast of Mexico. Two additional scales for paracetamol 
and sedatives are included, which act as relatively safe (negative control) and risky (positive control) drugs.
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Dataset 1. Raw data of risk perception to medicinal marijuana in 
medical students
http://dx.doi.org/10.5256/f1000research.12638.d179069
Discussion
In this study, we assessed the risk perceived by medical students 
toward the use of MM. Previous reports have analyzed the risk 
perception to several drug prescriptions; however, this is the first 
study that analyzes the risk perception to MM using the same 
instrument that these studies used.
Although several studies in the general population and among 
health professionals have shown a support for the legal use of 
MM9–12, physicians undoubtedly require solid knowledge of 
both its benefits and adverse effects if they want recommend it 
appropriately. Our results show that the risk perceived to MM 
(4.2 cm) is higher than paracetamol but lower than sedatives in 
Mexican medical students. Compared with other studies, the 
risk perceived is similar to the risk perceived to antibiotics, hypo-
cholesterolemia drugs, and antihypertensives (median range 
3–5 cm), but lower than that to nonsteroidal anti-inflammatory 
drugs (NSAIDs), antidepressants, and anticoagulants (median 
> 6 cm)6–8,13. Although the objective was not to establish whether 
perceived risk was adequate, we speculate that observed outcome 
is low. We think that a reasonable risk perception of MM should 
be more than 6, close to other drugs as sedatives, antidepres-
sants or anticoagulants.This due to the difficulty of dosing, spe-
cifically if it is smoked, and the frequency of adverse effects of 
MM. We speculate that students with risk perception values of 
MM lower than 5 could underestimate its adverse effects and 
probably could recommend it indiscriminately during their 
practice. More studies concerning this are needed.
On the other hand, the risk perception of paracetamol was low 
and is similar to that previously reported14. The implications of 
this finding could be the same as with MM; students could under-
estimate its adverse effects, which is mainly liver damage15. It is 
worth remembering that lack of awareness of potential harm 
from taking or administering paracetamol improperly in adults 
and adolescents is a cause of emergency department visits16.
An interesting result was the significant difference in risk per-
ception between those that self-reported smoking and alcohol 
consumption. The users of these recreational drugs had a lower risk 
perception of MM. In this sense, it has been proven in previous 
studies that tobacco and alcohol consumption are risk factors for 
the use of recreational marijuana17,18. In addition, the consumption 
of these drugs has been associated with support for legalization of 
recreational and MM19,20.
The risk perception observed could be due in part to attention from 
mass media regarding its potential uses. Previous studies have 
found an association between public support for MM and its 
coverage in media21,22. Another factor that could impact risk 
perception values, is the lack of formal courses regarding MM 
in the syllabus of students surveyed23. In this sense, previous 
studies have proven that formal courses of pharmacology 
increase risk perception toward common drugs like NSAIDs7. 
The design and implementation of formal courses regarding 
MM may have the same impact.
Finally, we consider that our results should be interpreted with 
caution, as it is possible that our findings may not be general-
ized to other countries, due to differences in teaching methods. 
Replication in others countries, especially where the use of MM 
has been recently made legal, is needed. Although the risk percep-
tion of drugs has been studied with visual scales, the development 
of other instruments could improve the assessment.
Conclusions
The risk perception of MM was 4.22 in medical students of the 
northeast of Mexico. With the legalization of MM in Mexico, 
formal courses regarding dosing, and adverse and beneficial 
effects of MM will be needed in medical schools.
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